[1] American Psychiatry Association(APA).Diagnostic and statistical manual of mental disorder: DSM-IV,4th edition[S].Washington DC: American Psychiatric Association,1994.
[2] FAVA M,KENDLER K S.Major depressive disorder[J].Neuron,2000,28(2): 33.
[3] DER-AVAKIAN A,MARKOU A.The neurobiology of anhedonia and other reward-related deficits[J].Trends Neurosci,2012,35(1): 68-77.
[4] CHAN R C,WANG Y,HUANG J,et al.Anticipatory and consummatory components of the experience of pleasure in schizophrenia: cross-cultural validation and extension[J].Psychiatry Res,2010,175(1-2): 181-183.
[5] MCGLINCHEY J B,ZIMMERMAN M,YOUNG D,et al.Diagnosing major depressive disorder Ⅷ: are some symptoms better than others?[J].J Nerv Ment Dis,2006,194: 785-790.
[6] GARD D E,GARD M G,KRING A M,et al.Anticipatory and consummatory components of the experience of pleasure: a scale development study[J].J Res Pers,2006,40: 1086-1102.
[7] WATSON D,WEBER K,ASSENHEIMER J S,et al.Testing a tripartite model: Ⅰ.Evaluating the convergent and discriminant validity of anxiety and depression symptom scales[J].J Abnorm Psychol,1995,104: 3-14.
[8] 刘文华,陈楚侨,黄敏.抑郁症的内表现型: 快感缺失及其测量方法[J].心理科学进展,2010,18(2): 271-281.
[9] TREADWAY M T,ZALD D H.Reconsidering anhedonia in depression: lessons from translational neuroscience[J].Neurosci Biobehav Rev,2011,35(3): 537-55.
[10] BERRIDGE K C,ROBINSON T E.What is the role of dopamine in reward: hedonic impact,reward learning,or incentive salience？[J].Brain Res Brain Res Rev,1998,28(3): 309-369.
[11] KACZMAREK H J,KIEFER S W.Microinjections of dopaminergic agents in the nucleus accumbens affect ethanol consumption but not palatability[J].Pharmacol Biochem Behav,2000,66: 307-312.
[12] HNASKO T S,SOTAK B N,PALMITER R D.Morphine reward in dopamine-deficient mice[J].Nature,2005,438: 854-857.
[13] GERSHON A A,VISHNE T,GRUNHAUS L.Dopamine D2-like receptors and the antidepressant response[J].Biol Psychiatry,2007,61: 145-153.
[14] PECINA S,SMITH K S,BERRIDGE K C.Hedonic hot spots in the brain[J].Neuroscientist,2006,12: 500-511.
[15] ZUBIETA J K,BUELLER J A,JACKSON L R,et al.Placebo effects mediated by endogenous opioid activity on mu-opioid receptors[J].J Neurosci,2005,25: 7754-7762.
[16] PECINA S,BERRIDGE K C.Hedonic hot spot in nucleus accumbens shell: where do mu-opioids cause increased hedonic impact of sweetness？[J].J Neurosci,2005,25: 11777-11786.
[17] SMITH K S,TINDELL A J,ALDRIDGE J W,et al.Ventral pallidum roles in reward and motivation[J].Behav Brain Res,2009,196: 155-167.
[18] JAYARAM-LINDSTROM N,WENNBERG P,HURD Y L,et al.Effects of naltrexone on the subjective response to amphetamine in healthy volunteers[J].J Clin Psychopharmacol,2004,24: 665-669.
[19] STAHL S M.Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline[J].Biol Psychiatry,2000,48: 894-901.
[20] KUGAYA A,SENECA N M,SNYDER P J,et al.Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration[J].Neuropsychopharmacology,2003,28: 413-420.
[21] VOLKOW N D,WANG G J,FOWLER J S,et al.Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate[J].Am J Psychiatry,1998,155: 1325-1331.
[22] RAU K S,BIRDSALL E,HANSON J E,et al.Bupropion increases striatal vesicular monoamine transport[J].Neuropharmacology,2005,49: 820-830.
[23] DWOSKIN L P,RAUHUT A S,KING-POSPISIL K A,et al.Review of the pharmacology and clinical profile of bupropion,an antidepressant and tobacco use cessation agent[J].CNS Drug Rev,2006,12: 178-207.
[24] BRUIJNZEEL A W,MARKOU A.Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats[J].Synapse,2003,50: 20-28.
[25] PATERSON N E,BALFOUR D J,MARKOU A.Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell[J].Eur J Neurosci,2007,25: 3099-3108.
[26] PALMATIER M I,LEVIN M E,MAYS K L,et al.Bupropion and nicotine enhance responding for nondrug reinforcers via dissociable pharmacological mechanisms in rats[J].Psychopharmacology(Berl),2009,207: 381-390.
[27] WALTER M,HENNING A,GRIMM S,et al.The relationship between aberrant neuronal activation in the pregenual anterior cingulate,altered glutamatergic metabolism,and anhedonia in major depression[J].Arch Gen Psychiatry,2009,66: 478-486.
[28] BOYER P,TASSIN J P,FALISSART B,et al.Sequential improvement of anxiety,depression and anhedonia with sertraline treatment in patients with major depression[J].J Clin Pharm Ther,2000,25(5): 363-371.
[29] di GIANNANTONIO M,di IORIO G,GUGLIELMO R,et al.Major depressive disorder,anhedonia and agomelatine: an open-label study[J].J Biol Regul Homeost Agents,2011,25(1): 109-114.
[30] MARTINOTTI G,SEPEDE G,GAMBI F,et al.Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study[J].J Clin Psychopharmacol,2012,32(4): 487-491.
[31] di GIANNANTONIO M,MARTINOTTI G.Anhedonia and major depression: the role of agomelatine[J].Eur Neuropsychopharmacol,2012,22(Suppl 3): S505-510.
[32] 徐丽华,傅文青,唐柳,等.认知情绪调节对强迫、人际关系、抑郁的影响[J].东南大学学报: 医学版,2011,30(5): 751-754.
[33] COFFMAN S J,MARTELL C R,DIMIDJIAN S,et al.Extreme nonresponse in cognitive therapy: can behavioral activation succeed where cognitive therapy fails？[J].J Consult Clin Psychol,2007,75: 531-541.
[34] DICHTER G S,FELDER J N,PETTY C,et al.The effects of psychotherapy on neural responses to rewards in major depression[J].Biol Psychiatry,2009,66: 886-897. |
